Loading...
XASX
IMR
Market cap224mUSD
Jul 11, Last price  
1.26AUD
1D
-4.55%
1Q
-14.29%
IPO
2.44%
Name

Imricor Medical Systems Inc

Chart & Performance

D1W1MN
No data to show
P/E
P/S
233.54
EPS
Div Yield, %
Shrs. gr., 5y
18.45%
Rev. gr., 5y
8.44%
Revenues
959k
+55.86%
703,919565,5971,342,573639,704702,161696,267816,011615,568959,424
Net income
-30m
L+31.23%
-5,494,861-6,710,723-7,297,118-14,798,147-13,076,801-20,556,113-17,534,184-22,625,902-29,692,831
CFO
-16m
L-20.34%
-4,051,414-5,647,803-6,340,013-6,627,993-12,230,689-17,488,546-16,821,693-19,551,255-15,573,910
Earnings
Jul 29, 2025

Profile

Imricor Medical Systems, Inc., a medical device company, designs, manufactures, sells, and distributes magnetic resonance imaging (MRI) compatible products for cardiac catheter ablation procedures in the United States. The company's principal products include the Advantage-MR EP Recorder/Stimulator system, an EP recording system and integrated cardiac stimulator; Vision-MR Ablation Catheter, which is used as an indication for treating type I atrial flutter; and Vision-MR Dispersive Electrode that is used to minimize eddy currents induced on the conductive pads during MR scanning. It also performs contract research, as well as licenses its intellectual property for use in implantable devices. Imricor Medical Systems, Inc. was incorporated in 2006 and is headquartered in Burnsville, Minnesota.
IPO date
Aug 30, 2019
Employees
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
959
55.86%
616
-24.56%
816
17.20%
Cost of revenue
17,256
17,471
18,076
Unusual Expense (Income)
NOPBT
(16,297)
(16,855)
(17,260)
NOPBT Margin
Operating Taxes
178
Tax Rate
NOPAT
(16,297)
(16,855)
(17,438)
Net income
(29,693)
31.23%
(22,626)
29.04%
(17,534)
-14.70%
Dividends
Dividend yield
Proceeds from repurchase of equity
5,848
4,301
BB yield
-6.55%
-7.83%
Debt
Debt current
468
668
867
Long-term debt
22,089
11,193
5,930
Deferred revenue
727
Other long-term liabilities
5,900
2,740
493
Net debt
6,850
10,907
772
Cash flow
Cash from operating activities
(15,574)
(19,551)
(16,822)
CAPEX
(78)
(83)
(239)
Cash from investing activities
(75)
(83)
(239)
Cash from financing activities
30,334
8,214
3,943
FCF
(16,483)
(13,672)
(18,220)
Balance
Cash
15,708
832
5,688
Long term investments
122
338
Excess cash
15,660
923
5,985
Stockholders' equity
(142,253)
(164,974)
7,510
Invested Capital
161,989
169,382
7,235
ROIC
ROCE
EV
Common stock shares outstanding
223,999
156,611
150,495
Price
1.36
138.60%
0.57
56.16%
0.37
-63.68%
Market cap
304,639
241.26%
89,268
62.51%
54,931
-59.53%
EV
311,489
100,175
55,702
EBITDA
(15,376)
(16,855)
(16,548)
EV/EBITDA
Interest
48
178
Interest/NOPBT